Mody R, et al. - Using data from the HealthCore Integrated Research Database, researchers assessed adherence (proportion of days covered ≥ 80%), persistence, glycemic control, and costs at 12-month follow-up for patients with type 2 diabetes (T2D) initiating dulaglutide vs liraglutide or exenatide once weekly. They found that patients with T2D initiating dulaglutide treatment had significantly higher adherence and persistence vs those initiating liraglutide or exenatide once weekly. Patients with dulaglutide also showed a significantly greater reduction in glycated hemoglobin (HbA1c) vs those with liraglutide and a greater—but non-significant—reduction in HbA1c vs those with once weekly exenatide. The mean diabetes-related total costs for dulaglutide vs liraglutide were $16,174 and $16,694, respectively. Overall, they proposed that dulaglutide is an important treatment option that may help to improve results in patients with T2D due to the significance of adherence and its role in glycemic control.